Table 3. Anti-FXa-IIa activities among different adherence groups in peak and trough concentration.

Anti-FXa-IIa activities	MGLS	N	Mean	SD	95% CI	P
Rivaroxaban anti-Xa-peak	High adherence	107	269.1	12.2	244.8–293.3	–
	Intermediate adherence	37	244.0	19.6	204.4–283.7	–
	Total	144	262.6	10.4	242.1–283.2	0.294
Rivaroxaban anti-Xa-trough	High adherence	104	46.5	4.0	38.6–54.4	–
	Intermediate adherence	31	45.2	5.7	33.5–56.9	–
	Total	135	46.2	3.3	39.6–52.8	0.870
Dabigatran anti-IIa-peak	High adherence	76	156.9	14.3	128.5–185.4	–
	Intermediate adherence	37	144.9	15.2	114.1–175.7	–
	Low adherence	6	188.4	79.9	−17.1 to 394.0	–
	Total	119	154.8	10.9	133.2–176.4	0.688
Dabigatran anti-IIa-trough	High adherence	74	70.2	6.9	56.5–83.9	–
	Intermediate adherence	37	66.6	10.0	46.3–86.9	–
	Low adherence	6	70.1	33.7	−16.5 to 156.7	–
	Total	117	69.0	5.6	58.0–80.0	0.957

Unit of anti-FXa-IIa activities: ng/mL. MGLS, Morisky, Green, and Levine Adherence Scale; CI, confidence interval; SD, standard deviation.